CN114288292B - Application of aromatic compound as activator of nerve Cong Su protein-B2 in preparation of medicine for treating osteoporosis - Google Patents
Application of aromatic compound as activator of nerve Cong Su protein-B2 in preparation of medicine for treating osteoporosis Download PDFInfo
- Publication number
- CN114288292B CN114288292B CN202111502631.XA CN202111502631A CN114288292B CN 114288292 B CN114288292 B CN 114288292B CN 202111502631 A CN202111502631 A CN 202111502631A CN 114288292 B CN114288292 B CN 114288292B
- Authority
- CN
- China
- Prior art keywords
- protein
- aromatic compound
- formula
- osteoporosis
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001491 aromatic compounds Chemical class 0.000 title claims abstract description 24
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 239000012190 activator Substances 0.000 title abstract description 9
- 210000005036 nerve Anatomy 0.000 title abstract description 9
- 101710132618 Protein B2 Proteins 0.000 title abstract description 8
- 101710201789 Ribonucleoside-diphosphate reductase 1 subunit beta Proteins 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 238000011282 treatment Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 39
- 230000014509 gene expression Effects 0.000 abstract description 37
- 210000002997 osteoclast Anatomy 0.000 abstract description 27
- 210000000988 bone and bone Anatomy 0.000 abstract description 24
- 101710100551 Plexin-B2 Proteins 0.000 abstract description 19
- 102100034383 Plexin-B2 Human genes 0.000 abstract description 18
- 108090000623 proteins and genes Proteins 0.000 abstract description 13
- 210000000963 osteoblast Anatomy 0.000 abstract description 10
- 238000011161 development Methods 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 2
- 230000003111 delayed effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 101000761509 Homo sapiens Cathepsin K Proteins 0.000 description 9
- 102000004067 Osteocalcin Human genes 0.000 description 9
- 108090000573 Osteocalcin Proteins 0.000 description 9
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 9
- 238000011529 RT qPCR Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- -1 small molecule compound Chemical class 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 102100024940 Cathepsin K Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101710151542 Nuclear factor of activated T-cells, cytoplasmic 1 Proteins 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000009806 oophorectomy Methods 0.000 description 4
- 230000002188 osteogenic effect Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 101000713935 Mus musculus Tudor domain-containing protein 7 Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 2
- 101150074062 Tnfsf11 gene Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 238000007469 bone scintigraphy Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010603 microCT Methods 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 206010057175 Mass conditions Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 101001098398 Mus musculus Osteocalcin Proteins 0.000 description 1
- 102100034404 Nuclear factor of activated T-cells, cytoplasmic 1 Human genes 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 101710086070 Plexin-B Proteins 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 229940124605 anti-osteoporosis drug Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 125000005340 bisphosphate group Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000010258 osteoblastogenesis Effects 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of an aromatic compound serving as an activator of a nerve Cong Su protein-B2 in preparation of a medicament for treating osteoporosis. The aromatic compound is preferably a compound shown in a formula II, and the compound shown in the formula II can obviously increase the expression level of Plexin-B2 protein and genes and activate downstream signal paths of the Plexin-B2 protein and genes, and can also obviously promote the generation of osteoblasts and inhibit the generation of the osteoclasts, so that the bone mass is obviously increased, the development of osteoporosis is delayed, a research basis and a theoretical basis are provided for developing medicaments for treating OP, and the aromatic compound can be applied to the preparation of medicaments for preventing and/or treating the osteoporosis.
Description
Technical Field
The invention belongs to the technical field of medicine and biochemistry, and particularly relates to an application of an aromatic compound serving as an activator of nerve Cong Su protein-B2 (Plexin-B2) in preparation of a medicament for treating osteoporosis.
Background
Osteoporosis (OP) is one of the most common metabolic diseases of bone and is characterized by reduced bone mass, increased bone fragility due to destruction of bone microstructure, and increased risk of fracture. OP mainly includes senile osteoporosis and postmenopausal osteoporosis, and the high-frequency population is the elderly and postmenopausal women. In China, the first few of common diseases and frequently encountered diseases of OP are jumped, the incidence rate rises year by year, the total incidence rate is 12.4%, the incidence rate of the aged over 65 years is over 50%, wherein the incidence rate of fracture is close to one third, the risks of disability and total cause death of the aged, especially the aged females, are obviously increased, and heavy economic and medical burden is brought to society.
Currently, clinical anti-osteoporosis drugs mainly include basic supplements (e.g., calcium agents, vitamin D), drugs for inhibiting bone resorption (e.g., bisphosphates), and drugs for promoting bone formation (e.g., parathyroid hormone). From the current treatment situation, the problems of general treatment effect, high long-term treatment cost, certain side effects, poor patient compliance and the like exist, so that the development of effective anti-osteoporosis medicines is urgently needed.
The nerve Cong Su protein (Plexins) is a widely distributed family of transmembrane receptor proteins, and the nerve Cong Su protein-B2 (Plexin-B2) is a member of the Plexin-B subfamily, and no relevant report has been found so far regarding the use of Plexin-B2 activators for the preparation of a medicament for the treatment of osteoporosis.
Disclosure of Invention
The invention aims to solve the technical problem of unsatisfactory treatment effect of the existing medicament for treating osteoporosis, and provides an aromatic compound serving as an activator of nerve Cong Su protein-B2 and application thereof in preparation of the medicament for treating osteoporosis. The invention can provide a research basis and a theoretical basis for developing a new medicament for treating osteoporosis.
The specific technical scheme provided by the invention is as follows.
The invention provides an application of an aromatic compound as an activator of a nerve Cong Su protein-B2, wherein the aromatic compound is one or more of a compound shown in a formula I, a compound shown in a formula II and a compound shown in a formula III;
the invention also provides application of an aromatic compound in preparing a medicament for preventing and/or treating diseases related to the nerve Cong Su protein-B2, wherein the aromatic compound is one or more of a compound shown in a formula I, a compound shown in a formula II and a compound shown in a formula III.
The invention also provides application of the aromatic compound in preparing a medicament for preventing and/or treating osteoporosis, wherein the aromatic compound activator is one or more of a compound shown in a formula I, a compound shown in a formula II and a compound shown in a formula III;
in the present invention, the aromatic compound is preferably the compound represented by formula I, the compound represented by formula II, or the compound represented by formula III, for example, the compound represented by formula II.
In the invention, K784-9621 (shown as a compound in a formula II) is used as one of small molecule activators of Plexin-B2, and can obviously increase the expression level of Plexin-B2 protein and gene and activate downstream signal channels.
In the invention, L087-0246 (shown as a compound shown as a formula I), K784-9621 (shown as a compound shown as a formula II) and G856-6766 (shown as a compound shown as a formula III) can inhibit the expression level of an osteoclast gene CTSK-mRNA.
The invention also provides application of an aromatic compound as a gene Runx2, sp7 and Alp expression promoter, wherein the aromatic compound is one or more of the compound shown in the formula I, the compound shown in the formula II and the compound shown in the formula III.
In the present invention, the aromatic compound is preferably the compound represented by formula I, the compound represented by formula II, or the compound represented by formula III, for example, the compound represented by formula II.
The invention also provides application of an aromatic compound as an expression inhibitor of genes NFATc1, rank and CTSK, wherein the aromatic compound is one or more of the compound shown in the formula I, the compound shown in the formula II and the compound shown in the formula III.
In the present invention, the aromatic compound is preferably the compound represented by formula I, the compound represented by formula II, or the compound represented by formula III, for example, the compound represented by formula II.
The invention also provides application of the aromatic compound in preparing a medicament for preventing and/or treating postmenopausal osteoporosis, wherein the aromatic compound is shown in a formula II.
The reagents and materials used in the present invention are commercially available.
The invention has the positive progress effects that:
in the invention, L087-0246 (shown as a compound shown as a formula I), K784-9621 (shown as a compound shown as a formula II) and G856-6766 (shown as a compound shown as a formula III) can inhibit the expression level of an osteoclast gene CTSK-mRNA. In particular, K784-9621 of the present invention can inhibit the formation of osteoclasts and promote the formation of osteoblasts, thereby increasing the bone mass and delaying the development of osteoporosis. Specifically:
(1) The K784-9621 can obviously promote the generation of in vitro osteoblasts, and the expression of the osteogenesis related genes Runx2, sp7 and Alp of the K784-9621 stem prognosis is obviously increased compared with that of a control group;
(2) The K784-9621 can obviously inhibit the generation of in vitro osteoclasts, and the expression of the osteoclast related genes NFATc1, rank and CTSK after the K784-9621 stem prognosis is obviously reduced compared with a control group;
(3) K784-9621 improves bone mass, increases bone volume fraction (BV/TV), bone trabecular number (Tb.N), bone trabecular thickness (Tb.Th) and bone formation rate, and decreases bone trabecular separation (Tb.Sp);
(4) K784-9621 increases OCN + Is capable of reducing Trap + Is an osteoclast of (a).
Drawings
FIG. 1A is a block diagram of a small molecule compound of example 1;
FIG. 1B is a schematic diagram of qPCR results of the effect of each small molecule compound on the expression level of the osteoclast gene CTSK;
FIG. 2 is a schematic representation of the effect of K784-9621 on the Plexin-B2 protein; wherein, FIG. 2A is a schematic diagram showing the results of K784-9621 promoting expression of Plexin-B2 protein; FIG. 2B is a graph of a statistical analysis of the promotion of expression of the Plexin-B2 protein by K784-9621;
FIG. 3 is a schematic diagram showing the qPCR results of K784-9621 for promoting expression of the Plexin-B2 gene;
FIG. 4 is a graph showing the qPCR results of K784-9621 for promoting the expression of osteogenic related genes;
FIG. 5 is a schematic representation of the effect of K784-9621 on osteoclasts; FIG. 5A is a schematic representation of K784-9621 staining with anti-tartrate acid phosphatase (Trap) inhibiting osteoclast formation; FIG. 5B Trap Positive (Trap + ) A statistical analysis chart of osteoclast number; FIG. 5C is a graph showing the qPCR results of K784-9621 inhibiting the expression of an osteoclast-associated gene;
FIG. 6 is a graph showing the effect of K784-9621 on bone mass and bone morphology parameters in osteoporotic mice; wherein, FIG. 6A is a three-dimensional reconstruction of bone scan of postmenopausal osteoporosis mice after ovariectomy by intraperitoneal injection of K784-9621; FIG. 6B is a schematic diagram of micro-CT bone parameter analysis of mice under different treatment conditions;
FIG. 7 is a graph showing the effect of K784-9621 on the number of osteoblasts positive for OCN in osteoporotic mice; wherein FIG. 7A is a schematic representation of mouse Osteocalcin (OCN) staining under different treatment conditions, arrows indicate OCN positivity (OCN) + ) Is a cell of (a); FIG. 7B shows the OCN of mice under different treatment conditions + A statistical analysis chart of cell number;
FIG. 8 is a graph showing the effect of K784-9621 on the number of osteoclasts positive for the Trap of an osteoporosis mouse; FIG. 8A is a schematic representation of mouse Trap staining under different treatment conditions, with arrows indicating Trap positivity (Trap + ) Is a cell of (a); FIG. 8B shows the mouse Trap positivity (Trap + ) Statistical analysis of cell number.
Detailed Description
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications.
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications.
Example 1a small molecule compound capable of binding with Plexin-B2 was obtained by computer drug-assisted design screening, and a small molecule compound having an effect on the expression level of the osteoclast gene CTSK was screened;
1. preparing 10mg/ml stock solution: (1) the small molecular compounds (shown in Table 1) are obtained through computer drug aided design screening and are purchased from chemdiv company and centrifuged at 1000r/min for 5mins; (2) in an ultra-clean workbench, 100ul of DMSO is sucked and added into 1mg of powder, and the powder is repeatedly blown and evenly mixed; (3) packaging the mixed liquid, and storing at-20deg.C.
2. Preparing 10ug/ml working solution: (1) taking the split-packed storage solution, and rewarming at room temperature; (2) working fluid was prepared in a ratio of 1ul stock solution per 1ml of medium for subsequent cell experiments.
3. The mononuclear cells of the bone marrow of a mouse are obtained by 1X 10 ≡ 5 Cell/well density was inoculated into alpha-MEM medium containing macrophage colony stimulating factor (M-CSF, 30 ng/ml), nuclear factor κB receptor activating factor ligand (Rankl, 100 ng/ml), 10% fetal bovine serum, 1% double antibody, and divided into Control group (Control) (not administered group) and each small molecule compound treatment group (structure of each compound is shown in FIG. 1A), liquid was changed every 3 days, and after differentiation culture for 9 days, trap staining was performed to detect the number of osteoclasts; cell RNA was extracted after 7-8 days of differentiation culture, and the expression level of the osteoclast gene CTSK-mRNA was detected by qPCR (qPCR specific experimental method reference: chang-Jun Li, et al Long noncoding RNA Bmncr regulates mesenchymal stem cell fate during skeletal imaging. J Clin Invest,2018,128 (12): 5251-5266.).
Referring to fig. 1B, table 1, each value is expressed as the mean ± SD of three assays. P <0.05, P <0.01, P <0.001 compared to Control group.
TABLE 1
| Group of | Relative expression levels of CTSK |
| Control | 20.000±2.843 |
| L087-0246 | 11.200±5.432* |
| G639-1239 | 23.981±7.250 |
| 1109-0033 | 14.520±4.744 |
| K784-9621 | 3.943±1.347** |
| K781-0814 | 14.406±0.379 |
| G717-1369 | 18.382±2.935 |
| D678-0039 | 16.458±4.076 |
| T630-1975 | 17.133±5.219 |
| G856-6766 | 12.559±0.254* |
The effect of 9 compounds shown in fig. 1A on the expression level of the osteoclast gene CTSK is shown in table 1, fig. 1B. This result demonstrates that K784-9621 has the most pronounced inhibitory effect on the osteoclast gene CTSK.
Example 2K784-9621 can significantly promote expression of Plexin-B2, promote osteoblast formation and inhibit osteoclast formation
(1) The specific experimental procedure for detecting Plexin-B2 protein and gene expression is as follows:
the mononuclear cells of the bone marrow of a mouse are obtained by 1X 10 ≡ 5 Cell/well density was inoculated in alpha-MEM medium containing macrophage colony stimulating factor (M-CSF, 30 ng/ml), 10% fetal bovine serum, 1% diabody, and divided into Control group (Control), K784-9621 treatment group (K784-9621). After 48 hours of K784-9621 intervention, cellular proteins and RNAs were extracted and the expression levels of the Plexin-B2 proteins and genes were detected by WB and q-PCR, respectively. (specific experimental methods for WB reference: chang-Jun Li, et al Long noncoding RNA Bmncr regulates mesenchymal stem cell fate during skeletal, ing. J Clin Invest,2018,128 (12): 5251-5266.).
For specific results, see fig. 2 and 3, tables 2 and 3, each numerical value is expressed as the mean ± SD of three assays. P <0.05, P <0.01, P <0.001 compared to Control group.
TABLE 2
| Group of | Plexin-B2 relative expression level |
| Control | 0.442±0.051 |
| K784-9621 | 0.990±0.175* |
From FIGS. 2A and 2B, it can be seen that K784-9621 significantly increased the level of Plexin-B2 protein expression compared to the DMSO-treated Control group.
TABLE 3 Table 3
| Group of | Plexin-B2 relative expression level |
| Control | 1.000±0.095 |
| K784-9621 | 1.534±0.057** |
As can be seen from FIG. 3, K784-9621 significantly increased the gene expression level of Plexin-B2 compared to the Control group.
(2) The specific experimental procedure for detecting the expression level of the osteogenic related gene is as follows:
according to a cell density of 5X 10 3 /cm 2 Mesenchymal Stem Cells (BMSCs) were inoculated into an alpha-MEM medium containing 0.1mM dexamethasone, 10mM beta-glycerophosphate, 50mM ascorbic acid-2-phosphate, and 10% fetal bovine serum, and divided into a Control group (Control) and a K784-9621-treated group (K784-9621), and after a single liquid change every 3 days, cellular RNAs were extracted and the expression level of the osteogenic related gene was detected by qPCR after 6 days of differentiation culture.
For specific results, see fig. 4, table 4, each value is expressed as mean ± SD of three assays. P <0.05, P <0.01, P <0.001 compared to Control group.
TABLE 4 Table 4
| Group of | Runx2 relative expression level | Sp7 relative expression level | Relative expression level of Alp |
| Control | 1.059±0.073 | 1.039±0.101 | 1.000±0.067 |
| K784-9621 | 1.722±0.085** | 1.880±0.020** | 1.898±0.042*** |
As can be seen from FIG. 4 and Table 4, the expression levels of mRNA of the osteogenic related genes Runx2, sp7 and Alp after the treatment with K784-9621 were significantly increased as compared with the control group. This result demonstrates that K784-9621 can promote differentiation of BMSCs into osteoblasts.
(3) The specific experimental procedure for detecting the expression level of the osteoclast-associated gene is as follows:
the mononuclear cells of the bone marrow of a mouse are obtained by 1X 10 ≡ 5 Cell/well density seeded on macrophage colony stimulating factor (M-CSF, 30 ng/ml), nuclear factor kappa B receptor activating factorLigand (Rankl, 100 ng/ml), 10% fetal bovine serum and 1% double antibody in alpha-MEM culture medium are divided into a Control group (Control) and a K784-9621 treatment group (K784-9621), liquid is changed once every 3 days, and after differentiation culture for 9 days, trap staining is carried out to detect the number of osteoclasts; cell RNA was extracted after differentiation culture for 7-8 days, and the expression level of the osteoclast-associated gene was detected by qPCR.
Referring to fig. 5, table 5, each value is expressed as the mean ± SD of three assays. P <0.05, P <0.01, P <0.001 compared to Control group.
TABLE 5
From fig. 5A and 5B, table 5 shows that the number of osteoclasts was significantly reduced after the stem prognosis of K784-9621 compared to the control group.
TABLE 6
| Group of | Relative expression level of NFATc1 | Rank relative expression level | CTSK relative expression level |
| Control | 1.000±0.133 | 1.000±0.124 | 1.000±0.113 |
| K784-9621 | 0.517±0.032** | 0.444±0.054** | 0.143±0.054** |
As can be seen from FIG. 5C and Table 6, the expression level of mRNA of the osteoclast-associated genes NFATc1, rank, CTSK was significantly reduced after the treatment with K784-9621, as compared with the control group. This result suggests that K784-9621 can inhibit osteoclastogenesis.
Example 3K 784-9621 can increase bone mass in postmenopausal osteoporosis mice by promoting bone formation and inhibiting bone resorption
Postmenopausal osteoporosis (PMO) is a metabolic bone disease that results in significant loss of bone mass due to estrogen decline, and is a high turnover type of osteoporosis that is characterized by a significant increase in osteoclastic production, a slight increase in osteoblastic cells, and eventually a significant decrease in bone mass due to greater bone resorption than bone formation. Since we observed earlier that K784-9621 can significantly inhibit osteoclastogenesis and promote osteoblastogenesis in vitro, we further hypothesize whether it has an improving effect on bone mass reduction in postmenopausal osteoporosis. Adaptively feeding C57BL/C mice for 1 week, dividing into a sham operation +velicle group (sham), an ovariectomy +velicle group (OVX) and an ovariectomy +K784-9621 group (K784-9621), injecting velicle or K784-9621 (70 mg/kg once a day) into the abdominal cavity after 1 week, weighing the mice in each group after 7 weeks of injection, taking blood from the apex of the heart, leaving a bilateral femur, fixing one femur with formaldehyde, placing the fixed femur in a sample tube for CT scanning, and then carrying out micro-CT analysis and three-dimensional reconstruction to observe bone mass conditions; the other femur was decalcified in 10% EDTA decalcification solution for 3 weeks, paraffin-embedded, and sectioned, and then stained with OCN and Trap, respectively.
For specific results, see FIGS. 6-8, tables 7-9, each value is expressed as the mean+ -SD of three assays. P <0.05, < P <0.01, < P <0.001, compared to sham group; compared to OVX group, #p <0.05, #p <0.01, #p <0.001.
TABLE 7
From the three-dimensional reconstruction of the bone scan of fig. 6A, it can be seen that the OVX group showed significantly reduced bone mass after ovariectomy compared to sham group, while the K784-9621 treated mice showed significantly increased bone mass compared to OVX group. As can be seen from the mir-CT analysis parameters of FIG. 6B, the bone volume fraction (BV/TV), the number of trabeculae (Tb.N), and the thickness of trabeculae (Tb.Th) were all significantly reduced in the OVX group compared to the sham group, while the trabeculae separation (Tb.Sp) was significantly increased, and K784-9621 improved the bone mass parameters described above in the ovariectomized mice. This result demonstrates that K784-9621 can improve bone mass loss in postmenopausal osteoporosis mice.
TABLE 8
| Group of | OCN + Osteoblasts (N/mm) |
| sham | 8.723±0.861 |
| OVX | 8.690±0.813 |
| K784-9621 | 10.616±0.556## |
As can be seen from FIGS. 7A and 7B, the OVX group OCN is compared with the sham group + Is not obvious; k784-9621 significantly increased the number of osteoblasts compared to the OVX group. This result suggests that K784-9621 may promote osteoblast formation in vivo.
TABLE 9
| Group of | Trap + Is an osteoclast (N/mm) |
| sham | 3.682±0.189 |
| OVX | 8.392±0.587*** |
| K784-9621 | 6.226±0.731### |
As can be seen from FIGS. 8A and 8B, the OVX group Trap compares with the sham group + Is significantly increased; k784-9621 significantly reduced the number of osteoclasts compared to the OVX group. This result demonstrates that K784-9621 can inhibit osteoclastogenesis in vivo.
The above results together demonstrate that K784-9621 can promote osteoblast formation by inhibiting osteoclast formation, thereby increasing bone mass in postmenopausal osteoporosis mice.
In the foregoing, the protection scope of the present invention is not limited to the preferred embodiments of the present invention, and any simple changes or equivalent substitutions of the technical solutions that can be obviously obtained by those skilled in the art within the technical scope of the present invention disclosed in the present invention fall within the protection of the present invention.
Claims (1)
1. Use of an aromatic compound in the manufacture of a medicament for the prevention and/or treatment of osteoporosis, the aromatic compound being a compound of formula II;
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111502631.XA CN114288292B (en) | 2021-12-10 | 2021-12-10 | Application of aromatic compound as activator of nerve Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
| CN202310570877.3A CN116650481A (en) | 2021-12-10 | 2021-12-10 | Application of aromatic compound as activator of nerve Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
| CN202310571517.5A CN116650495B (en) | 2021-12-10 | 2021-12-10 | Application of aromatic compound as activator of nervous Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111502631.XA CN114288292B (en) | 2021-12-10 | 2021-12-10 | Application of aromatic compound as activator of nerve Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310570877.3A Division CN116650481A (en) | 2021-12-10 | 2021-12-10 | Application of aromatic compound as activator of nerve Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
| CN202310571517.5A Division CN116650495B (en) | 2021-12-10 | 2021-12-10 | Application of aromatic compound as activator of nervous Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114288292A CN114288292A (en) | 2022-04-08 |
| CN114288292B true CN114288292B (en) | 2023-06-13 |
Family
ID=80967310
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310571517.5A Active CN116650495B (en) | 2021-12-10 | 2021-12-10 | Application of aromatic compound as activator of nervous Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
| CN202310570877.3A Pending CN116650481A (en) | 2021-12-10 | 2021-12-10 | Application of aromatic compound as activator of nerve Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
| CN202111502631.XA Active CN114288292B (en) | 2021-12-10 | 2021-12-10 | Application of aromatic compound as activator of nerve Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310571517.5A Active CN116650495B (en) | 2021-12-10 | 2021-12-10 | Application of aromatic compound as activator of nervous Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
| CN202310570877.3A Pending CN116650481A (en) | 2021-12-10 | 2021-12-10 | Application of aromatic compound as activator of nerve Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN116650495B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116650495B (en) * | 2021-12-10 | 2024-04-19 | 中南大学湘雅医院 | Application of aromatic compound as activator of nervous Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9611210A (en) * | 1995-10-23 | 1999-12-28 | Zymogenetics Inc | Compositions and processes for treating deficient bone conditions |
| MXPA03003007A (en) * | 2000-10-06 | 2003-07-14 | Tanabe Seiyaku Co | Aliphatic nitrogenous five-membered ring compounds. |
| US20040014676A1 (en) * | 2001-07-09 | 2004-01-22 | Ramalinga Dharanipragada | SRC kinase inhibitors useful for treating osteoporosis |
| JP2007308465A (en) * | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | Method for treatment of inflammatory disease, autoimmune disease or bone resorption abnormality |
| CA2588369C (en) * | 2007-05-11 | 2016-08-02 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| MX343640B (en) * | 2011-05-13 | 2016-11-15 | Nat Univ Corp Tokyo Medical & Dental Univ | Osteogenesis promoter. |
| WO2013129620A1 (en) * | 2012-02-28 | 2013-09-06 | 国立大学法人東京医科歯科大学 | Composition for increasing bone mass |
| CN104127862A (en) * | 2014-08-14 | 2014-11-05 | 武汉大学 | Application of Semaphorin 4D in preventing and treating bone metabolic diseases |
| BR112017017825A2 (en) * | 2015-02-23 | 2018-04-10 | Seagull Therapeutics Sas | unnatural semaphorins 3 and their medical use |
| EP3271015B8 (en) * | 2015-03-16 | 2023-11-01 | Ogeda N.V. | Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat |
| JP6632116B2 (en) * | 2015-08-20 | 2020-01-15 | 国立大学法人広島大学 | Agent for suppressing osteoclast formation and / or function, agent for promoting osteoclast formation and / or function, and method for screening for agent for suppressing or promoting osteoclast formation and / or function |
| CN107151236B (en) * | 2016-03-03 | 2021-04-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 2, 3-epoxysuccinyl derivative and preparation method and application thereof |
| CN107569488A (en) * | 2017-11-02 | 2018-01-12 | 中国科学院西北高原生物研究所 | Application and its medicine of the rutaecarpin in osteosporosis resistant medicament is prepared |
| CN113456645A (en) * | 2021-07-09 | 2021-10-01 | 浙江大学医学院附属邵逸夫医院 | Application of DMXAA in preparing medicine for preventing and treating osteoporosis |
| CN116650495B (en) * | 2021-12-10 | 2024-04-19 | 中南大学湘雅医院 | Application of aromatic compound as activator of nervous Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
-
2021
- 2021-12-10 CN CN202310571517.5A patent/CN116650495B/en active Active
- 2021-12-10 CN CN202310570877.3A patent/CN116650481A/en active Pending
- 2021-12-10 CN CN202111502631.XA patent/CN114288292B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN116650495A (en) | 2023-08-29 |
| CN116650495B (en) | 2024-04-19 |
| CN114288292A (en) | 2022-04-08 |
| CN116650481A (en) | 2023-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Atkins et al. | Expression of osteoclast differentiation signals by stromal elements of giant cell tumors | |
| Zhang et al. | The BMSC-derived exosomal lncRNA Mir9-3hg suppresses cardiomyocyte ferroptosis in ischemia-reperfusion mice via the Pum2/PRDX6 axis | |
| US10314834B2 (en) | Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation | |
| CN110934873B (en) | Anti-aging drug D/S targeting aged cells in tissue microenvironment and application thereof | |
| Liu et al. | Lipoxin A4 suppresses osteoclastogenesis in RAW264. 7 cells and prevents ovariectomy-induced bone loss | |
| CN114288292B (en) | Application of aromatic compound as activator of nerve Cong Su protein-B2 in preparation of medicine for treating osteoporosis | |
| Hassumi et al. | PPAR-γ agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis | |
| Wang et al. | Protective effects of punicalagin on osteoporosis by inhibiting osteoclastogenesis and inflammation via the NF-κB and MAPK pathways | |
| Downs et al. | PTHrP stimulates prostate cancer cell growth and upregulates aldo–keto reductase 1C3 | |
| Gaines et al. | Mouse neutrophils lacking lamin B-receptor expression exhibit aberrant development and lack critical functional responses | |
| Li et al. | Gastrodin protects myocardial cells against hypoxia/reoxygenation injury in neonatal rats by inhibiting cell autophagy through the activation of mTOR signals in PI3K-Akt pathway | |
| US20110124712A1 (en) | Anti-cancer composition comprising microrna molecules | |
| CN113456645A (en) | Application of DMXAA in preparing medicine for preventing and treating osteoporosis | |
| Agarwal et al. | HBcrAg, HBV-RNA declines in a phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg-positive and negative virally suppressed subjects with hepatitis B | |
| EP3412297A1 (en) | Composition for inhibiting cancer metastasis using apoptotic cells | |
| CN114209700A (en) | New application of Salubrinal in preparation of medicines for treating bone marrow mesenchymal stem cell aging | |
| JP2022549397A (en) | Use of the JWA gene and related compounds for anti-aging | |
| Wong et al. | A novel RANKL-targeted furoquinoline alkaloid ameliorates bone loss in ovariectomized osteoporosis through inhibiting the NF-κB signal pathway and reducing reactive oxygen species | |
| US20170266253A1 (en) | Antithetical regulation of endothelial ace and ace2 by brg1-foxm1 complex underlies pathological cardiac hypertrophy | |
| WO2006102611A2 (en) | Therapeutic agents for the treatment of leukemia | |
| JP4168276B2 (en) | Dioscorea sp. Extract and its medical use | |
| TW201720448A (en) | Treatment of cancer with lncRNA AOC4P | |
| WO2022109246A1 (en) | Use of microrna inhibition to prevent and treat osteoarthritis and other inflammatory diseases | |
| WO2020017112A1 (en) | Eicosanoid production promoter | |
| CN106924757B (en) | Application of miR-449c-5p and mimic thereof in preparation of products for treating and preventing heart valve diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |